SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
Tigher
Lv1
90 积分
2022-09-08 加入
最近求助
最近应助
互助留言
Time to Second Objective Disease Progression (PFS2): An Emerging Clinical Trial Endpoint with Regulatory and Reimbursement Implications
2天前
已完结
Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer
3天前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
4天前
已完结
Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy
14天前
已完结
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
14天前
已完结
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
14天前
已完结
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
20天前
已完结
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
20天前
已完结
Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials
20天前
已完结
Progression-free survival: it is time for a new name
20天前
已完结
没有进行任何应助
感谢
2天前
感谢
3天前
感谢
4天前
感谢
14天前
感谢
20天前
感谢
29天前
感谢
1个月前
感谢
1个月前
感谢
2个月前
感谢
2个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论